Unicycive Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
UNCY Nasdaq 8731 https://unicycive.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Unicycive Therapeutics Inc

Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report® - Jun 9th, 2023 1:00 pm
Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit Outlook - May 17th, 2023 10:03 am
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update - May 16th, 2023 12:29 pm
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress - Apr 24th, 2023 11:00 am
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update - Mar 31st, 2023 11:00 am
Shareholders have faith in Unicycive Therapeutics (NASDAQ:UNCY) as stock climbs 36% in past week, taking one-year gain to 99% - Mar 8th, 2023 11:04 am
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury - Mar 7th, 2023 2:00 pm
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb - Mar 6th, 2023 12:00 pm
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers - Mar 3rd, 2023 2:15 pm
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings - Feb 27th, 2023 12:00 pm
Unicycive: The Company Developing Key Kidney Therapies - Feb 17th, 2023 3:35 pm
Unicycive: This Biotech Company Receives Promising Results From New Trial - Feb 6th, 2023 2:59 pm
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea - Feb 2nd, 2023 1:30 pm
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings - Jan 23rd, 2023 12:00 pm
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023 - Jan 5th, 2023 12:00 pm
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock - Dec 29th, 2022 4:31 pm
Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study - Dec 28th, 2022 2:21 pm
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb - Dec 28th, 2022 1:30 pm
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom - Dec 22nd, 2022 12:00 pm
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - Dec 9th, 2022 1:00 pm